@article{ref1,
title="Reinforcing effects of oral Delta9-THC in male marijuana smokers in a laboratory choice procedure",
journal="Psychopharmacology",
year="2005",
author="Hart, Carl L. and Haney, Margaret and Vosburg, Suzanne K. and Comer, Sandra D. and Foltin, Richard W.",
volume="181",
number="2",
pages="237-243",
abstract="RATIONALE: Oral Delta-9-tetrahydrocannabinol (Delta(9)-THC; Marinol) is medically available for the treatment of nausea associated with cancer chemotherapy and for wasting syndromes related to HIV/AIDS. Little is known about its reinforcing effects. OBJECTIVE: This study was conducted to characterize the reinforcing effects of oral Delta(9)-THC in experienced marijuana smokers under controlled laboratory conditions. METHODS: Ten healthy male marijuana users completed this 17-day residential study. On days 2, 6, 10, and 14, at 0900 h, participants received a &quot;sample&quot; oral dose of Delta(9)-THC (0, 10, 20 mg) and an alternative reinforcer, a 2 US dollars voucher (redeemable for cash at study's end). Over the next 3 days, they had 11 opportunities to self-administer either the sampled dose of Delta(9)-THC or to receive a 2 US dollars voucher. RESULTS: Participants chose active Delta(9)-THC (10 and 20 mg) more often than placebo (<two selections vs approximately four selections, respectively). However, they chose active Delta(9)-THC on less than 50% of choice opportunities. Both active Delta(9)-THC doses produced significant increases in &quot;positive&quot; subjective effects, impaired psychomotor performance, and increased heart rate, relative to the placebo conditions. CONCLUSION: These data indicate that oral Delta(9)-THC may have modest abuse liability in experienced marijuana smokers.<p /><p>Language: en</p>",
language="en",
issn="0033-3158",
doi="10.1007/s00213-005-2234-2",
url="http://dx.doi.org/10.1007/s00213-005-2234-2"
}